Abstract Library

#1795 Results from a Phase 2, Open-Label, Multicenter, Randomized Study of the Novel, Octreotide (Oct) Subcutaneous (SC) Depot Formulation in Patients with Functioning Neuroendocrine Tumors (NETs) and Acromegaly Previously Treated with Long-Acting Octreotide

Introduction: Oct sc depot is a novel, ready to use formulation administered via a thin needle.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Pavel M, Borson-Chazot , Hörsch D, Lahner , Pivonello R,

Keywords: octreotide sc depot, NET,

#210 Clinical Characteristics of the 5,160 Patients Included in the French Database of the French Endocrine Tumor Group (GTE)

Introduction: An endocrine tumor database was initiated in 2005 by the French endocrine tumor group (GTE). Today, it comprises 5,160 patients, 70% of whom were diagnosed from 2000.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Borson-Chazot F, Baudin E, Lombard C, Ruszniewski P, Niccoli P,

Keywords: gastroenteropancreatic endocrine tumor, database, clinical characteristics ,